Cardiac Biomarkers Market | Growth, Trends, and Forecast (2020

ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the Report
- Key Market Trends
- Competitive Landscape
- Major Players
TABLE OF CONTENTS

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Biomarkers enable the timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment. The increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements is expected to drive the market in the forecast period.

Scope of the Report

As per the scope of the report, Biomarkers have an essential role in the diagnosis, management, risk stratification, and clinical decision-making in the patients suffering from disease. Cardiac biomarkers are measurable and quantifiable biological parameters, which are detected in the blood and serve as indices for physiological and pathological assessment.

By Type
		Creatine Kinase
		Troponins
		Myoglobin
		Ischemia Modified Albumin
		Others

By Application
		Congestive Heart Failure
		Acute Coronary Syndrome
		Myocardial Infarction
		Atherosclerosis
		Others

By Location Of Testing
		Point of Care Testing
		Laboratory Testing

Geography

North America
	United States
	Canada
	Mexico

Europe
	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle-East and Africa
	GCC
	South Africa
	Rest of Middle-East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Myocardial Infarction Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Others. The key factor contributing to the growth of the segment is the rising number of cardiovascular disorders. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. The average age of first myocardial infarction is 65.6 years old for men and 72.0 years old for women. Many companies are focusing on developing breakthrough products for the treatment of cardiovascular disease. Hence, with the rising government initiatives and wide applications of biomarkers in cardiac diagnostics, the market is expected to grow over the forecast period.

To understand key trends, Download Sample Report

North America Dominates the Cardiac Biomarkers Market

The cardiac biomarkers market holds the largest share in North America region. According to the American Heart Association around 2,300 Americans die of cardiovascular disease each day. The cardiac markers help in monitoring the prognosis of certain condition with greater accuracy and providing the most effective treatment to the patients Hence, with the rising concerns regarding cardiovascular disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

To understand geography trends, Download Sample Report.

Competitive Landscape

The global players in the cardiac biomarkers market are - Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Major Players

You can also purchase parts of this report. Do you want to check out a section wise price list?

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 Increasing Prevalence of Cardiovascular Diseases
  2. 4.2.2 Technological Advancements in the Cardiac Biomarkers
  3. 4.2.3 Growing Funding From Public and Private Organizations for R&D
3. 4.3 Market Restraints
  1. 4.3.1 Stringent Regulatory Framework
4. 4.4 Porter's Five Forces Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Type
  1. 5.1.1 Creatine Kinase
  2. 5.1.2 Troponins
  3. 5.1.3 Myoglobin
  4. 5.1.4 Ischemia Modified Albumin
  5. 5.1.5 Others
2. 5.2 By Application
  1. 5.2.1 Congestive Heart Failure
  2. 5.2.2 Acute Coronary Syndrome
  3. 5.2.3 Myocardial Infarction
  4. 5.2.4 Atherosclerosis
  5. 5.2.5 Others
3. 5.3 By Location Of Testing
  1. 5.3.1 Point of Care Testing
  2. 5.3.2 Laboratory Testing
4. 5.4 Geography
  1. 5.4.1 North America
    1. 5.4.1.1 United States
    2. 5.4.1.2 Canada
    3. 5.4.1.3 Mexico
  2. 5.4.2 Europe
    1. 5.4.2.1 Germany
    2. 5.4.2.2 United Kingdom
    3. 5.4.2.3 France
    4. 5.4.2.4 Italy
    5. 5.4.2.5 Spain
    6. 5.4.2.6 Rest of Europe
  3. 5.4.3 Asia-Pacific
    1. 5.4.3.1 China
    2. 5.4.3.2 Japan
    3. 5.4.3.3 India
    4. 5.4.3.4 Australia
    5. 5.4.3.5 South Korea
    6. 5.4.3.6 Rest of Asia-Pacific
  4. 5.4.4 Middle-East and Africa
    1. 5.4.4.1 GCC
    2. 5.4.4.2 South Africa
    3. 5.4.4.3 Rest of Middle-East and Africa
  5. 5.4.5 South America
    1. 5.4.5.1 Brazil
    2. 5.4.5.2 Argentina
    3. 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Abbott Laboratories
  2. 6.1.2 Becton, Dickinson and Company
  3. 6.1.3 BioMerieux
  4. 6.1.4 Bio-Rad Laboratories, Inc.
  5. 6.1.5 Danaher Corporation
  6. 6.1.6 F. Hoffmann-La Roche AG
  7. 6.1.7 Randox Laboratories
  8. 6.1.8 Siemens Healthineers
  9. 6.1.9 Thermo Fisher Scientific

*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject to Availability

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments